A recently approved brand drug for bipolar disorder will have little impact on how health plans cover these medications, experts say. Health plans will continue to encourage the use of less expensive generic bipolar drugs.
The brand drug, Allergan plc’s Vraylar (cariprazine), was approved by the FDA in May to treat depressive episodes associated with bipolar 1 disorder in adults. The drug also was previously approved to treat manic or mixed episodes associated with bipolar 1 disorder and schizophrenia in adults. It is an oral, once-daily atypical antipsychotic.